![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00127179 |
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
Condition | Intervention | Phase |
---|---|---|
Benign Prostatic Hyperplasia |
Drug: MK0906, finasteride / Duration of Treatment: 48 weeks Drug: Comparator: placebo / Duration of Treatment: 48 weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia |
Estimated Enrollment: | 600 |
Study Start Date: | January 2004 |
Ages Eligible for Study: | 50 Years to 79 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2005_042 |
Study First Received: | August 3, 2005 |
Last Updated: | June 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00127179 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Finasteride Hyperplasia Prostatic Diseases Prostatic Hyperplasia Genital Diseases, Male |
Finasteride Hyperplasia Pathologic Processes Molecular Mechanisms of Pharmacological Action Prostatic Diseases |
Prostatic Hyperplasia Enzyme Inhibitors Genital Diseases, Male Pharmacologic Actions |